Microbiological Diagnostic Unit Public Health Laboratory, The University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Victoria, Australia.
Department of Microbiology & Immunology, The University of Melbourne at the Peter Doherty Institute for Infection & Immunity, Melbourne, Victoria, Australia.
Clin Infect Dis. 2021 Dec 6;73(11):e3912-e3920. doi: 10.1093/cid/ciaa972.
Multiresistant organisms (MROs) pose a critical threat to public health. Population-based programs for control of MROs such as carbapenemase-producing Enterobacterales (CPE) have emerged and evaluation is needed. We assessed the feasibility and impact of a statewide CPE surveillance and response program deployed across Victoria, Australia (population 6.5 million).
A prospective multimodal intervention including active screening, carrier isolation, centralized case investigation, and comparative pathogen genomics was implemented. We analyzed trends in CPE incidence and clinical presentation, risk factors, and local transmission over the program's first 3 years (2016-2018).
CPE case ascertainment increased over the study period to 1.42 cases/100 000 population, linked to increased screening without a concomitant rise in active clinical infections (0.45-0.60 infections/100 000 population, P = .640). KPC-2 infection decreased from 0.29 infections/100 000 population prior to intervention to 0.03 infections/100 000 population in 2018 (P = .003). Comprehensive case investigation identified instances of overseas community acquisition. Median time between isolate referral and genomic and epidemiological assessment for local transmission was 11 days (IQR, 9-14). Prospective surveillance identified numerous small transmission networks (median, 2; range, 1-19 cases), predominantly IMP and KPC, with median pairwise distance of 8 (IQR, 4-13) single nucleotide polymorphisms; low diversity between clusters of the same sequence type suggested genomic cluster definitions alone are insufficient for targeted response.
We demonstrate the value of centralized CPE control programs to increase case ascertainment, resolve risk factors, and identify local transmission through prospective genomic and epidemiological surveillance; methodologies are transferable to low-prevalence settings and MROs globally.
多药耐药菌(MRO)对公共卫生构成重大威胁。已出现针对产碳青霉烯酶肠杆菌科(CPE)等 MRO 的基于人群的控制项目,需要对此进行评估。我们评估了在澳大利亚维多利亚州(人口 650 万)实施的全州范围 CPE 监测和应对计划的可行性和效果。
实施了一种包括主动筛查、携带者隔离、集中病例调查和比较病原体基因组学的前瞻性多模式干预措施。我们分析了该计划实施的头 3 年(2016-2018 年)中 CPE 发病率和临床表现、危险因素以及本地传播的趋势。
在研究期间,CPE 病例的检出率逐渐增加,达到 1.42 例/10 万人,这与筛查的增加有关,而活跃的临床感染并没有相应增加(0.45-0.60 例/10 万人,P=0.640)。KPC-2 感染从干预前的 0.29 例/10 万人降至 2018 年的 0.03 例/10 万人(P=0.003)。全面的病例调查确定了一些在海外社区获得的感染。本地传播的分离株转介到基因组和流行病学评估之间的中位时间为 11 天(IQR,9-14)。前瞻性监测发现了许多小的传播网络(中位数为 2;范围为 1-19 例),主要是 IMP 和 KPC,中位 SNP 之间的距离为 8(IQR,4-13);同一序列型的聚类之间的低多样性表明,仅基因组聚类定义不足以进行有针对性的反应。
我们证明了集中式 CPE 控制项目的价值,该项目可通过前瞻性的基因组和流行病学监测来提高病例检出率、解决危险因素并确定本地传播;这些方法可转移到低流行地区和全球的 MRO 中。